10x Genomics Q3 2026 Confirms Structural Weakness Amid Flat Revenue and Reliance on IP Windfalls

What happened

10x Genomics reported its third quarter 2026 financial results, and the announcement likely mirrors the challenging trends seen throughout 2025: flat product revenue, sharp instrument declines, and a reliance on spatial consumables growth to offset weakness elsewhere. The master report's analysis indicates that products and services revenue (excluding IP settlements) has been flat to slightly down, with instruments falling over 30% year-over-year in recent quarters. Gross margins and cash flow have been artificially boosted by one-time litigation settlements, which are now largely behind the company, exposing the underlying operating losses. With NIH funding uncertainty and academic capital budget pressures, the outlook for a return to growth remains dim without a major commercial or product breakthrough. The Q3 2026 report is unlikely to change the bearish thesis that TXG is overvalued at current levels.

Implication

The Q3 2026 results reinforce the prior assessment that TXG's equity value is not supported by fundamentals, with core revenue essentially flat and profitability still distant. Even if spatial consumables continue to grow at high-teens, they are not enough to offset declining instruments and Chromium consumables, so total product revenue may continue to drift lower. Management's cost cuts have improved near-term cash flow, but at the expense of commercial coverage, which could further hamper future growth. The pending NIH budget decisions and ongoing IP litigation add additional uncertainty that could negatively impact both revenue and margins. Given the stock's recent rebound to near $20, the margin of safety is minimal, and the base case value of $16 implies downside risk of around 20%.

Thesis delta

The announcement does not materially change the thesis; it is consistent with the prior 'Potential Sell' rating. The evidence of structural decline in the core single-cell franchise and over-reliance on non-recurring IP income remains unchanged. Any hope for a recovery is premature until management demonstrates sustained organic growth ex-IP, which has not occurred.